Propanc Biopharma, Inc. PPCB
1.72 USD -0.10 (-5.77%)
Nov 5, 2026, 1:30 PM EST
1.63 Day range 1.83
1.63 52-week range 315.00
- YTD
- -98.72%
- 1 year
- -99.42%
News
globenewswire.com Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer MELBOURNE, Australia, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
globenewswire.com Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
benzinga.com Propanc Biopharma Continues Clinical Development Program For Propanc Proenzyme; Targets February 2027 For Its First Clinical Site Initiation Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer,
globenewswire.com Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients "The continued advancement- benzinga.com Propanc Biopharma Announces New Preclinical Data Supporting Potential Of PRP To Treat Chemotherapy Resistance In Pancreatic Cancer; PRP Monotherapy Reduced Cancer Cell Proliferation By ~50–54% And Suppressed Long-term Clonogenic Survival By Up To 59% Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer,
globenewswire.com Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability We envision PRP as a long-term, metronomic therapy that minimizes the threat of recurrence while enabling patients to better respond to standard treatments
globenewswire.com CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans "
benzinga.com Propanc Biopharma Announces 1-For-10 Reverse Stock Split, Effective Oct. 26 Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer,
globenewswire.com Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
benzinga.com Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer,
globenewswire.com Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells MELBOURNE, Australia, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
globenewswire.com Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer MELBOURNE, Australia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
defenseworld.net Propanc Biopharma Inc (NASDAQ:PPCB) Sees Significant Increase in Short Interest Propanc Biopharma Inc (NASDAQ: PPCB - Get Free Report) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 71,162…
globenewswire.com Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib MELBOURNE, Australia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…- benzinga.com Propanc Biopharma Registers Resale Of 6,500,000 Shares Of Common Stock https://www.sec.gov/ix?doc=/Archives/edgar/data/0001517681/000149315226045770/forms-1.htm
globenewswire.com Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results "The Company is poised to capitalize on the foundation set- benzinga.com Propanc Biopharma Analysis Of PRP Against Clinical Datasets From Erasca Demonstrates PRP Does Not Exhibit RAS Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer,
globenewswire.com Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca's Phase 1 ERAS-0015…
benzinga.com Propanc Biopharma Issues Comparative Analysis Of Lead Candidate PRP Against Clinical Datasets From RAS-Targeted Programs, Including Revolution Medicines’ Daraxonrasib And Erasca’s Pan-RAS Molecular Glue ERAS-0015 Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer,
globenewswire.com Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
globenewswire.com Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) shares moved…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) stock moved…
benzinga.com Why Elastic Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket Elastic NV (ESTC) stock rose 21.8% in pre-market trading after reporting strong Q1 results and raising FY27 guidance. Other top gainers include WHLR, QNRX, AEMD, NA, SOLS, HYNE, GAP, AFRM, and ARKR.…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock…
benzinga.com Crude Oil Moves Higher; Dollar General Shares Gain After Upbeat Q2 Earnings U.S. stocks traded higher, Dow up 0.20%, NASDAQ up 1.05%, S&P 500 up 0.47%. Tech shares jumped 2.4% while consumer staples fell 1%. Dollar General gained 5% on strong earnings. Propanc Biopharma…
benzinga.com Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results Propanc Biopharma Inc. (NASDAQ:PPCB) stock surged on Thursday after compelling preclinical and early translational data for its primary drug candidate, PRP, focused on treating pancreatic ductal…
benzinga.com Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90% tumor inhibition and extended survival.
benzinga.com Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500 up 0.27%. Tech shares rose 2.2% while consumer staples fell 1.1%. Nvidia reported strong earnings.…
globenewswire.com Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
globenewswire.com Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP MELBOURNE, Australia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
globenewswire.com Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers Further improvements can be made with complementary treatment modalities such as PRP that target the way cancer cells become malignant, invasive and spread
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million. Organigram Global…- benzinga.com Propanc Biopharma Announces New Preclinical And Translational Data For Lead Candidate PRP In Pancreatic Ductal Adenocarcinoma Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer,
globenewswire.com Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models MELBOURNE, Australia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday's regular session. The company's market cap stands at $60.6 million. Bluejay Diagnostics (NASDAQ:BJDX)…
globenewswire.com Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program MELBOURNE, Australia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…- benzinga.com Propanc Biopharma Announces Publication Of Evaluation Of Recombinant Trypsinogen And Chymotrypsinogen In Peer-Reviewed Journal Microbial Cell Factories Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer,
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals…
benzinga.com Propanc Biopharma Signs MoU With Avance Clinical To Support Delivery Of The Company's Phase 1B Trial For Lead Candidate PRP For Advanced Solid Tumors Importantly, both parties intend to approach the collaboration in a spirit of openness, scientific rigor, and shared problem-solving, with the goal of advancing PRP efficiently from FIH into…- benzinga.com 11 Health Care Stocks Moving In Thursday's Intraday Session Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma…
benzinga.com Propanc Biopharma Initiates First Tranche Of $500K Stock Buyback Plan Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer,- benzinga.com 10 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Friedman Industries Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket Friedman Industries Inc (NASDAQ: FRD) rose in pre-market trading after posting strong Q4 earnings. Other gainers include BYAH, VSME, ADTX, EDHL, GMM, HKIT, RKTO, ASYS, and PWRL. Losers include GELS,…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Industrials and Enliven Therapeutics lead gains. Dana Inc and Oracle Corp down. Oil up 0.7%, gold down 0.7%.…
benzinga.com Dow Jumps Over 250 Points; US Initial Jobless Claims Rise US stocks up, Dow gains 250 pts. Dow up 0.58% while NASDAQ up 0.67%. Materials shares jump 1.5%, communication services down 1.3%. Jobless claims up.- benzinga.com Propanc Biopharma Announces $5M Common Stock Buyback Plan Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer,…